Pharmacokinetics of teicoplanin in Chinese patients undergoing CAPD
Abstract number: 1733_877
Qi H., Ma X., Zhang P., Gao L., Cui H., Hou F.
Objective: To define a dose regimen of teicoplanin for Chinese patients undergoing CAPD (continue ambulatory peritoneal dialysis) so that they achieve trough drug serum levels above 10 mg/L.
Methods: Eight CAPD patients with acute respiratory system infection (seven with upper respiratory tract infection) of Gram-positive cocci were included in this study. At least seven dose of 400 mg teicoplanin were administered intravenously. After three 400 mg teicoplanin q12h loading doses, patients were given a repeated dose at 24 hour interval, then q72h for at least three times. Concentrations of teicoplanin in samples collected from peripheral vein and excluded dialysis fluid after the fourth dosages and 48, 72, 96 hours after the last dosage were determined by a microbiological assay.
Results: Mean Cmax was 63.57±16. 90 mg/L, mean AUC072 at steady state (AUCss) was 921.51±147.22 mgh/L, mean half life (t1/2) was 76.89±21.06 h, mean total clearance rates (CLt) was7.69±0.61 mL/h/kg clearance rates of peritoneal dialysis (CLPD) was 1.66±0.62/h/kg Mean volumes distribution at steady state (Vss) was 40.16±9.10 l, mean serum concentration at steady state (Cav) was 12.69±1.82 mg/L, Trough serum levels above 10 mg/L of most patients were found at 48 hr after the administration (10.03±2.41 mg/L), and mean serum concentration at 72 hr after the administration was 9.05±3.81 mg/L. Concentration of 96 h after last dose was 7.70±0.87 mg/L. The serum drug concentration of one patient whose total creatinine clearance rate was 38l/week (3.77 mL/min) showed that the concentration at 72 hours after administration was higher (17.94 mg/L) than the concentration at 48 hours (12.75 mg/L). The Clinical efficacy rate and bacterial eradication rates was 100%. Two patients experienced anorexia one might be related to primary diseases. There was no adverse effect observed on the anuric patient who had been given teicoplanin for a period of 22 days because of complicating G+ coccus panaritium and pneumonia.
Conclusion: It is proposed that teicoplanin is safety and efficacy on CAPD patient when administered according to the dose recommended by Sanofi-Aventis for renal failure patients with serious infection.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|